Free News Feed
Get our RSS Feed!
© Copyright 2026 StreetInsider.com
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
H.C. Wainwright analyst Ed Acre raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $400.00) while maintaining a Buy rating.
The analyst comments "We upgrade STLD to Peer Perform from Underperform, using updated steel price forecasts on Trump's pledged 25%... More
TD Cowen analyst Ritu Baral reiterated a Buy rating and $390.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL)
The analyst comments "4Q/FY24 Rezdiffra revs were $103M/$180M, at the top of the preannouncement range. As of YE24, 11.8K+ pts were on Tx.... More
Citi analyst David Lebowitz raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $469.00 (from $378.00) while maintaining a Buy rating.
The analyst comments "Madrigal reported 4Q24 financial results, exceeding sales expectations for Rezdiffra for the third consecutive quarter since its launch... More
Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($2.71), $1.77 better than the analyst estimate of ($4.48). Revenue for the quarter came in at $103.32 million versus the consensus estimate of $87.7 million.
For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.
... More